Ozempic vs Wegovy: Same Drug, Different Use & Dose

Both contain semaglutide, so the active drug is identical. Wegovy is FDA-approved specifically for weight loss and goes up to a slightly higher dose (2.4 mg vs 2 mg weekly), so on paper it has a marginally higher weight-loss ceiling. In practice, the better choice is the one that matches your diagnosis and that your insurance will cover. People without diabetes are usually prescribed Wegovy.

Sometimes, but only under medical guidance. Because both are semaglutide, a clinician can transition you while matching the dose. People often switch when their goal shifts (e.g., from diabetes control to dedicated weight management) or when insurance coverage changes. Never switch on your own — dose titration matters to limit nausea and side effects.

Insurance frequently covers Ozempic for Type 2 diabetes but excludes weight-loss drugs like Wegovy, so out-of-pocket costs can be higher. Both have also faced supply shortages. Coverage rules vary widely by plan — check our Ozempic insurance coverage guide and confirm your specific benefits before starting, including exact list prices and how compounded semaglutide pricing compares.

Yes, because they are the same drug. The most common side effects are nausea, diarrhea, constipation, and reduced appetite, usually worst during dose increases. Wegovy's higher max dose can mean slightly more GI side effects for some people. Serious but rare risks (pancreatitis, gallbladder issues, thyroid C-cell warnings) apply to both. Mood and psychiatric changes, including new or worsening depression, have also been reported with semaglutide and are monitored for this GLP-1 drug class, though a clear causal link hasn't been established the way it has for the GI and gallbladder effects. Tell your prescriber promptly about any new mood changes, low mood, or thoughts of self-harm while on either drug, rather than waiting for a routine follow-up. Discuss your history with a doctor. One recent observational study did find semaglutide use linked to lower rates of psychiatric hospitalization in patients with bipolar disorder, a reassuring data point, though it does not establish semaglutide as protective.

Not through the on-label path. Ozempic is approved specifically for Type 2 diabetes, and Wegovy is approved for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, as covered above — a prescriber has to have a legitimate basis to prescribe outside those criteria, and most won't. If you don't meet either standard but still want medical support for weight, ask your doctor about the actual criteria for your case rather than requesting either drug specifically; some people qualify once BMI or a related condition is properly evaluated, and others are better served by a different approach entirely. Worth also knowing before you stop: see what typically happens after stopping either drug in our Ozempic weight regain guide, and how alcohol interacts with both in our Ozempic and alcohol guide.

No — semaglutide is not recommended during pregnancy or while breastfeeding, whether prescribed as Ozempic or Wegovy, and prescribing guidance advises stopping it well before a planned pregnancy given how long it stays active in the body. Since both drugs contain the same active ingredient, this guidance applies equally to either one. Blood sugar or weight management in pregnancy is a conversation for your OB or a maternal-fetal medicine specialist, not something to handle with an unsupervised medication switch.

There is an observed association under active research, not a confirmed causal link. A 2024 JAMA Ophthalmology study found a higher rate of nonarteritic anterior ischemic optic neuropathy (NAION) — a rare cause of sudden, usually one-eye vision loss from reduced blood flow to the optic nerve — among semaglutide users compared to non-users. Since both Ozempic and Wegovy are semaglutide, this signal applies to either one. Larger follow-up studies since then have found a smaller increase in relative risk than the original study suggested, and major eye-health organizations have urged caution interpreting the early results while calling for more research. NAION itself remains rare overall. Any sudden vision loss, blurring in one eye, or new visual field changes while on either drug should be treated as urgent — contact an eye doctor or go to urgent care immediately, and tell your prescriber.

Thirty pounds in three months is faster than what Wegovy's own trial data supports for most people. The STEP 1 trial found an average loss of about 14.9% of body weight over 68 weeks, roughly a year and a half. That pace builds gradually rather than front-loading into the earliest weeks. For someone starting at 200 pounds, that trial pace works out closer to 30 pounds spread across more than a year than compressed into 3 months. Pushing for a faster result than your body adjusts to raises the odds of nausea and diarrhea.